Background Dual blockade of the EGFR and VEGF pathways in EGFR-mutated metastatic
non-small-cell lung cancer (NSCLC) is supported by preclinical and clinical data, yet the …

Sensitizing mutations in the epidermal growth factor receptor (EGFR) predict response to
EGFR tyrosine kinase inhibitors (TKIs) and both first-and second-generation TKIs are …

Tumor angiogenesis is a frequent event in the development and progression of non-small
cell lung cancer (NSCLC) and has been identified as a promising therapeutic target. The …

Canadian consensus: a new systemic treatment algorithm for advanced EGFR-mutated non-small-cell
lung cancer Page 1 e146 Current Oncology, Vol. 27, No. 2, April 2020 © 2020 Multimed Inc …

Aim: To evaluate the comparative efficacy and safety of identified first-line therapies for
patients with EGFR mutation-positive (EGFR m+) advanced non-small-cell lung cancer …

Background: To establish and validate a nomogram to predict liver metastasis in patients
with small-cell lung cancer (SCLC). Methods: Information on patients diagnosed with SCLC …

Background Despite the likelihood of an initial response to an epidermal growth factor
receptor (EGFR) tyrosine kinase inhibitor (TKI), EGFR-mutant non–small-cell lung cancer …

The epidermal growth factor receptor (EGFR) has been implicated in a multiplicity of cancer-
related signal transduction pathways like cellular proliferation, adhesion, migration …

The vascular endothelial growth factor (VEGF) and receptor is a therapeutic target because
of the importance of this pathway in carcinogenesis. This pathway regulates and promotes …

Purpose In REVEL, patients with advanced non-small-cell lung cancer (aNSCLC) and
patients with increased tumor aggressiveness (rapid disease progression (RDP), platinum …